Description: Adagene Inc. is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Its proprietary pipeline is comprised of novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.
Home Page: www.adagene.com
ADAG Technical Analysis
Building C14
Suzhou,
215123
China
Phone:
86 512 8777 3632
Officers
| Name | Title |
|---|---|
| Dr. Peter P. Luo Ph.D. | Co-Founder, CEO & Chairman |
| Mr. Man Kin Tam M.B.A. | CFO & Director |
| Dr. Fangyong Du Ph.D. | Chief Technology Officer |
| Dr. Jc Xu M.D., Ph.D. | Chief Scientific Officer |
| Ms. Ami Celeste Knoefler | VP of Investor Relations & Corp. Communications |
| Ms. Ling Zhou | Head of HR |
| Dr. Qinghai Zhao | Chief Manufacturing Officer |
| Ms. Yan Li M.B.A. | Sr. VP of Bioinformatics & Information Technology |
| Ms. Xiaohong She | Sr. VP & Head of Clinical Operations |
| Dr. Guizhong Liu Ph.D. | Head of Biology & Pharmacology |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4335 |
| Price-to-Sales TTM: | 4.4993 |
| IPO Date: | 2021-02-09 |
| Fiscal Year End: | December |
| Full Time Employees: | 259 |